Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates  by Erikstrup, L.T. et al.
Antimicrobial susceptibility testing of Clostridium difficile using EUCAST
epidemiological cut-off values and disk diffusion correlates
L. T. Erikstrup1,2, T. K. L. Danielsen3, V. Hall4, K. E. P. Olsen5, B. Kristensen6, G. Kahlmeter7, K. Fuursted1 and U. S. Justesen3
1) Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, 2) Institute of Clinical Medicine, Aarhus University, Aarhus, 3) Department of
Clinical Microbiology, Odense University Hospital, Odense, Denmark, 4) Anaerobe Reference Unit, University Hospital of Wales, Cardiff, Wales, UK,
5) Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, 6) National Center for Infection Control, Statens Serum Institut,
Copenhagen, Denmark and 7) Department of Clinical Microbiology, Central Hospital, Va¨xjo¨, Sweden
Abstract
With the emergence of reduced susceptibility of Clostridium difficile to metronidazole and vancomycin the value of antimicrobial suscepti-
bility testing has increased. The aim of our study was to evaluate disk diffusion for susceptibility testing of C. difficile by comparing disk
diffusion results with MICs from gradient tests and to propose zone diameter breakpoint correlates for the EUCAST epidemiological
cut-off values (ECOFFs) recently published. We tested 211 clinical isolates of C. difficile, from patients with diarrhoea hospitalized at
Aarhus and Odense University Hospitals, Denmark. Furthermore, ten clinical isolates of C. difficile from the Anaerobe Reference Labo-
ratory, University Hospital of Wales, with known reduced susceptibility to either metronidazole or vancomycin, were included. Isolates
were tested with Etest gradient strips and disk diffusion towards metronidazole, vancomycin and moxifloxacin on Brucella Blood Agar
supplemented with hemin and vitamin K. We found an excellent agreement between inhibition zone diameter and MICs. For each MIC
value, the inhibition zones varied from 0 to 8 mm, with 93% of values within 6 mm for metronidazole, 95% of values within 4 mm for
vancomycin, and 98% of values within 4 mm for moxifloxacin. With proposed zone diameter breakpoints for metronidazole, vancomycin
and moxifloxacin of WT ‡ 23 mm, WT ‡ 19 and WT ‡ 20 mm, respectively, we found no very major errors and only major errors
below 2%. In conclusion, we suggest that disk diffusion is an option for antimicrobial susceptibility testing of C. difficile.
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Introduction
The incidence of Clostridium difficile infection (CDI) has been
increasing [1,2]. The standard antimicrobial therapy for CDI
is oral metronidazole or vancomycin [3,4]. However, emer-
gence of reduced susceptibility, especially towards metroni-
dazole [5–8] but also vancomycin [7,9], has been reported.
This emphasizes the need for antimicrobial susceptibility
testing of C. difficile and for a simple susceptibility testing
method for the routine clinical microbiology laboratory. The
Clinical and Laboratory Standards Institute (CLSI) currently
recommends the use of the agar dilution method (which is
the reference method in CLSI) or one of the gradient meth-
ods [10]. The agar dilution method is highly reproducible
and it is suitable for surveillance and evaluation of new anti-
microbials, but agar dilution is technically demanding and too
labour intensive for the routine laboratory.
Gradient tests are convenient in routine laboratories and
are suitable for single tests. Several studies have validated
the method for susceptibility testing of anaerobes [11,12].
However, the gradient tests are expensive. Disk diffusion is
inexpensive and simple to perform and a few studies have
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evaluated disk diffusion for antimicrobial susceptibility testing
of C. difficile [6,13,14].
If routine susceptibility testing of C. difficile was to be per-
formed, implementation of a simple and inexpensive method
such as the disk diffusion method would be attractive.
Accordingly, the aim of our study was to evaluate disk dif-
fusion for susceptibility testing of C. difficile by comparing disk
diffusion results with MICs from gradient tests and to pro-




Consecutive clinical isolates of C. difficile (n = 211) were col-
lected from patients with diarrhoea hospitalized at Aarhus
University Hospital (n = 110) in 2008 and Odense University
Hospital (n = 101) in 2010. Furthermore, 10 clinical isolates
of C. difficile from the Anaerobe Reference Laboratory, Uni-
versity Hospital of Wales, with known reduced susceptibility
to metronidazole (n = 4, MIC 1.5, 2, 2, 3 mg/L, EC-
OFF £ 2 mg/L) or vancomycin (n = 6, MIC 1.5, 2, 2, 2, 3,
3 mg/L, ECOFF £2 mg/L), were included.
Isolates were cultured on CCFA (cycloserine-cefoxitin-
fructose agar) (Statens Serum Institute (SSI) Diagnostica, Hil-
lerød, Denmark) and incubated in an anaerobic chamber
(Aarhus University Hospital, Concept 400, Ruskinn Technol-
ogy, Bridgend, UK; Odense University Hospital, MiniMACS
Anaerobic Workstation, Don Whitley Scientific, West York-
shire, UK) in an anaerobic atmosphere (10% H2, 10% CO2,
80% N2) at 37C for 48 h.
Characteristic colonies (morphology, colour and odour)
were identified further using a Prolin test (Amino-peptidase
Reagent, CH3COOH 2.5%, CH3CH2OH 60%) (Rosco Diag-
nostica, Taastrup, Denmark).
After identification the strains were swabbed on 5% blood
agar plates (SSI Diagnostica, Hillerød, Denmark) and incu-
bated in anaerobic atmosphere for 24 h before freezing. The
strains were stored in preservation broth (meat bouillon
with 10 % glycerol) at )80C.
Stored isolates were thawed and cultured on 5% blood
agar plates and incubated in an anaerobic atmosphere for
24 h before susceptibility testing was performed. The refer-
ence C. difficile strain ATCC 700057 was included for quality
control.
At Aarhus University Hospital real-time PCR was used for
the detection of C. difficile toxin genes [15]. At Odense Uni-
versity Hospital toxin production was verified with Immuno-
Card (Meridian, Cincinnati, USA).
Selected isolates were further characterized with PCR ri-
botyping. PCR ribotyping was performed with minor modifi-
cations according to O’Neill et al. [16] and Stubbs et al. [17].
The resulting band patterns were compared and named
according to the PCR ribotype of the reference strains.
Antimicrobial susceptibility testing
The antimicrobial agents tested were vancomycin, metroni-
dazole and moxifloxacin. Vancomycin and metronidazole
were chosen because of emergence of reduced susceptibility.
Moxifloxacin was chosen because it can be used for screen-
ing of C. difficile PCR ribotype 027.
Cultured isolates were suspended in thioglycollate bouil-
lon (SSI Diagnostica, Hillerød, Denmark) to a density of 1.0
McFarland. A sterile cotton swab was placed in the suspen-
sion. The inoculum was spread evenly over the entire sur-
face of the plate. All susceptibility tests were performed on
Brucella Blood Agar (9 cm in diameter) supplemented with
haemin and vitamin K (Becton Dickinson, Heidelberg, Ger-
many). CLSI [10] recommend this singular medium for sus-
ceptibility testing of anaerobes.
To optimize growth of C. difficile, plates were reduced for
18–24 h in an anaerobic atmosphere before use. For the
preparation of inoculum, inoculation and incubation we fol-
lowed the 15-15-15-minute rule as recommended by the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) (http://www.eucast.org).
MIC determination was performed by gradient test. Etest
strips (bioMe´rieux, Craponne, France) with metronidazole,
vancomycin and moxifloxacin were placed on Brucella Blood
Agar supplemented with haemin and vitamin K. Disk diffusion
was performed with Oxoid disks (Oxoid, Basingstoke, UK)
with vancomycin (5 lg), metronidazole (5 lg) and moxifloxa-
cin (5 lg) on Brucella Blood Agar supplemented with haemin
and vitamin K. Plates were incubated in anaerobic atmo-
sphere (as described above) for 24 h. The zone diameters
were read at 100% inhibition.
Statistical analysis
Results were analysed using STATA/IC 11.2 (Statacorp,
Texas, USA). Bivariable regression analysis was applied to
the paired log-transformed MIC vs. the untransformed zone
diameter. The error-rate bounded method developed by
Metzler and DeHaan [18] was used to describe discrepancy
between Etest and disk diffusion. Very major error (VME)
was recorded when isolates were susceptible by disk diffu-
sion and resistant by Etest (falsely susceptible) and major
error (ME) was recorded when isolates were susceptible by
Etest but resistant by disk diffusion (falsely resistant).
According to CLSI document M23-A3 [19], VME should be
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<1.5% and ME less than 3% for a large collection of unse-
lected clinical isolates.
Results
A total of 221 clinical isolates of C. difficile were tested. The
distribution of inhibition zone diameters and MICs for C. diffi-
cile isolates towards metronidazole, vancomycin and moxi-
floxacin are illustrated in the histograms (Fig. 1) as used by
EUCAST for demonstrating the relationship between MIC
and zone diameter.
The metronidazole distribution showed that for each MIC
value, the inhibition zones varied from 0 to 8 mm, with 93%
of the values within 6 mm. Only one of the four isolates
from Wales with known reduced susceptibility to metronida-
zole had an MIC above ECOFF but all four isolates had zone
diameters below 14 mm, compared with the consecutive
clinical isolates from Denmark, which all had zone diameters
above 23 mm. The four isolates with reduced susceptibility
towards metronidazole were typed with PCR ribotyping.
They belonged to PCR ribotypes 001 (n = 1), 106 (n = 1)
and 027 (n = 2).
The vancomycin distribution showed that for each MIC
value, the inhibition zones varied from 0 to 6 mm, with 95%
of values within 4 mm. The six isolates with known reduced
susceptibility to vancomycin had zone diameters between 15
and 19 mm, compared with the consecutive clinical isolates
from Denmark, which all had zone diameters above 18 mm.
Two of these six isolates had an MIC above the ECOFF as
defined by EUCAST and these two isolates had zone diame-
ters of 15 and 18 mm, respectively. The isolates with
reduced susceptibility towards vancomycin were also typed
with PCR ribotyping. They belonged to the same three PCR
ribotypes as found for the isolates with reduced susceptibility
to metronidazole: PCR ribotypes 001 (n = 2), 106 (n = 1)
and 027 (n = 3).
The moxifloxacin distribution showed that for each MIC
value, the inhibition zones varied from 0 to 5 mm, with 98%
of the values within 4 mm. We observed a group of eight
isolates between the WT and the resistant population. These
intermediate isolates all came from patients hospitalized at
the same department at Aarhus University Hospital. With
PCR ribotyping we found that they belonged to two PCR
ribotypes: PCR ribotype 066 (n = 6) or PCR ribotype 014/
020/077 (n = 2) (the collective name for PCR ribotype 014/
FIG. 1. Distribution of inhibition zone diameters (disk diffusion method) and MICs (gradient test) for 221 isolates of C. difficile tested against
metronidazole (5 lg disk), vancomycin (5 lg disk) and moxifloxacin (5 lg disk). Each isolate is represented in the zone diameter histogram in a
colour representing its MIC value.
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020/077 is well known, as these three PCR ribotypes cannot
always be divided).
Figures 2–4 show the scattergram of MICs and zone diam-
eters for all three antimicrobials. The solid horizontal line in
each scattergram represents the MIC ECOFF established by
EUCAST. The solid vertical line in each scattergram repre-
sents the zone diameter breakpoint, which best correlates to
the MIC ECOFFs determined by EUCAST. We calculated
VME and ME for the proposed breakpoints. For metronida-
zole we propose a zone diameter breakpoint of
WT ‡ 23 mm (no VME, 1.4% ME). For vancomycin we pro-
pose a zone diameter breakpoint of WT ‡ 19 mm (no VME,
0.5% ME). For moxifloxacin we propose a zone diameter
breakpoint of WT ‡ 20 mm (no VME, 1.8% ME) (Table 1).
Bivariable regression analysis showed an acceptable to
excellent correlation between the log-transformed MIC vs.
the untransformed zone diameter, thus the R2 was 0.75 for
metronidazole, 0.55 for vancomycin and 0.97 for moxifloxacin.
FIG. 2. Scattergram comparing metronidazole (5 lg disk) zone diameter with gradient test MICs tested against 221 clinical isolates of C. difficile.
The solid horizontal line represents the MIC ECOFF established by EUCAST. The solid vertical line represents the proposed zone diameter
breakpoint. The isolates with known reduced susceptibility towards metronidazole (n = 4) are marked with blue.
FIG. 4. Scattergram comparing moxifloxacin (5 lg disk) zone diame-
ter with gradient test MICs tested against 221 clinical isolates of
C. difficile. The solid horizontal line represents the MIC ECOFF
established by EUCAST. The solid vertical line represents the pro-
posed zone diameter. The 10 Welsh isolates were all resistant
towards moxifloxacin.
FIG. 3. Scattergram comparing vancomycin (5 lg disk) zone diam-
eter with gradient test MICs tested against 221 clinical isolates of
C. difficile. The solid horizontal line represents the MIC ECOFF
established by EUCAST. The solid vertical line represents the pro-
posed zone diameter breakpoint. The isolates with known
reduced susceptibility towards vancomycin (n = 6) are marked
with blue.
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Discussion
According to the CLSI procedural documents, susceptibility
testing is indicated for any organism that contributes to an
infection warranting antimicrobial chemotherapy if suscepti-
bility cannot reliably be predicted from existing antibiograms
[10]. C. difficile is an organism that can contribute to an infec-
tion warranting antimicrobial chemotherapy, and with the
changes in antimicrobial susceptibility, especially to metroni-
dazole, susceptibility testing is indicated and a simple suscep-
tibility testing method is needed.
We compared disk diffusion zone diameters with Etest
MICs, and using bivariable regression analysis we found an
acceptable to excellent agreement between disk diffusion
and Etest for all three antimicrobials tested. However, more
importantly, the agreement between disk diffusion and Etest
can be clearly visualized in the MIC-coloured zone diameter
histogram. In 1999 Wong et al. conducted a study with 100
clinical isolates of C. difficile where they compared disk diffu-
sion with Etest. The method used by Wong et al. resembles
our method except they used vancomycin disks with a disk
content of 30 lg instead of 5 lg, and the incubation time
was 48 h instead of 24 h. The authors concluded that the
correlation coefficients found for metronidazole (R = 0.574)
and vancomycin (R = 0.473) were too low to allow accurate
prediction of MIC using the disk diffusion test. This study has
often been cited for their conclusion. When the absolute
majority of isolates belong to the MIC wild-type population
(i.e. there are no or only an occasional resistant organism in
the population) a low correlation coefficient is to be
expected, hence the low R-value for vancomycin. On the
other hand, the R-value becomes more acceptable with the
presence of a resistant population. When dealing primarily
with organisms without resistance mechanisms, regression
analysis and regression lines are of little help or value.
Therefore, regression analysis should always be used with
caution [18,20,21]. For most reference strains, almost
regardless of species and antimicrobial agent, the aggregated
inhibition zone values, of repeated testing, form a distribu-
tion most often covering 6–8 mm [22]. For the 221 clinical
isolates of C. difficile tested towards metronidazole, vancomy-
cin and moxifloxacin, we found that for each MIC value, the
inhibition zones varied from 0 to 8 mm, with 93% of the val-
ues within 6 mm for metronidazole, 95% of values within
4 mm for vancomycin, and 98% of values within 4 mm for
moxifloxacin. Therefore, we conclude that there is an excel-
lent agreement between disk diffusion and the MIC as mea-
sured by Etest.
The disk diffusion method was able to detect reduced
susceptibility towards metronidazole. We found the popula-
tion of organisms with reduced susceptibility to be clearly
separated from the WT by 9 mm. The EUCAST established
ECOFF for metronidazole is £2 mg/L (http://www.eu-
cast.org; 12 February 2012). This is based on MIC-values in
4435 isolates from 10 studies performed with agar dilution
(Brucella agar and Wilkins–Chalgren agar) and gradient tests
on Brucella agar. In our study, isolates with MIC above
1 mg/L exhibited a marked decrease of 9 mm in inhibition
zone diameter, which explains the major error of 1.4%
(Fig. 2). This would indicate that either the ECOFF for met-
ronidazole should be £1 mg/L (instead of £2 mg/L as cur-
rently recommended) or there is method dependency
corresponding to a +/)1 dilution step difference in the
MIC-value. Several studies have shown that metronidazole
MICs obtained by Etest are slightly lower than MICs
obtained by agar dilution [11,23]. The broad EUCAST dis-
tribution could also be explained by the inclusion of PCR
ribotypes that are known to have reduced susceptibility to
metronidazole (e.g. PCR ribotype 001) [8]. For epidemiolog-
ical purposes we propose a zone diameter breakpoint of
WT ‡ 23 mm. Only four isolates from the WT had zone
diameters below 28 mm. These four isolates had zone
diameters between 23 and 25 mm, with corresponding
MICs of 0.5–1 mg/L. They were clearly separated from the
isolates with reduced susceptibility on the zone diameter
and these isolates were therefore included in the WT.
However, decreased effectiveness of metronidazole treat-
ment of CDI has been reported [24,25]. This is believed to
be due to suboptimal intraluminal concentrations of metro-
nidazole during CDI. This hypothesis is based upon the
pharmacokinetics and pharmacodynamics of metronidazole,
and the wide variability in metronidazole levels measured in
watery stools during acute CDI [26,27]. The changes in sus-
ceptibility to metronidazole have not yet been linked to
treatment failure [28]. However, it is possible that a slight
TABLE 1. Categorization of C. difficile as wild type or non-
wild type using a gradient test and the proposed disk diffu-
sion method. Zone diameter correlates to ECOFFs as
determined by EUCAST were used and very major errors











Metronidazole WT ‡ 23 WT £ 2 0 1.4
Vancomycin WT ‡ 19 WT £ 2 0 0.5
Moxifloxacin WT ‡ 20 WT £ 4 0 1.8
*Tentative zone diameter ECOFF for the proposed disk diffusion method.
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increase in MIC of metronidazole for C. difficile may contrib-
ute to insufficient faecal antimicrobial concentration to inhi-
bit bacterial growth.
For vancomycin the reduced susceptibility was not as
clear-cut, either by disk diffusion or Etest. Two of the six
isolates with known reduced susceptibility towards vancomy-
cin had an MIC above the EUCAST ECOFF (Fig. 2). With a
proposed zone diameter breakpoint of WT ‡ mm 19 these
two isolates with an MIC of 3 mg/L were separated from the
WT. With a major error of 0.5% we suggest that isolates
with zone diameters <19 mm be confirmed with an MIC.
The reduced susceptibility to vancomycin, as observed in this
study, probably has no clinical consequence as oral vancomy-
cin (125–250 mg every 6 h) generally yields faecal levels
>1000 mg/L in patients with CDI [29]. However, it indicates
that vancomycin resistance development needs to be closely
monitored.
Despite the fact that disk diffusion was able to separate
the intermediate and resistant population from the WT for
moxifloxacin we still had a major error of 1.8%. This is due
to the fact that MICs of the intermediate isolates were very
close to the ECOFF (Fig. 2). If the disk diffusion method with
moxifloxacin was to be used for screening (e.g. PCR ribo-
type 027) we propose a zone diameter breakpoint of
WT ‡ 20 mm because this would enable us to distin-
guish between the WT and the intermediate and resistant
populations.
With the emergence of reduced susceptibility towards
metronidazole and vancomycin, the value of antimicrobial
susceptibility testing of C. difficile has increased. A simple
susceptibility testing method is needed and based on our
results the disk diffusion method is an option. We found an
excellent agreement between inhibition zone diameters by
disk diffusion and MICs by Etest. Disk diffusion was able to
distinguish between the WT and resistant and intermediate
populations and disk diffusion was able to detect reduced
susceptibility towards metronidazole and vancomycin.
Therefore, we conclude that the disk diffusion method is a
reliable option for antimicrobial susceptibility testing of
C. difficile.
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